Key result
AAV9 viral vector delivery of Sfrp1 attenuated TAC-induced cardiac dysfunction and improved systolic and diastolic functions by inhibiting Wnt signaling pathway-mediated apoptosis in mice.
Why the study?
Does AAV9-mediated Sfrp1 gene delivery improve cardiac function and reduce apoptosis in mice with TAC-induced heart failure?
Population
Mice with transverse aortic constriction (TAC)-induced heart failure model
Comparison
Recombinant adeno-associated virus 9 vector… vs TAC mice without AAV9-Sfrp1 treatment
Design
Preclinical
Authors
Loading...
May inform future gene therapy strategies in HF; leaves open clinical translation from murine data.
Does AAV9-mediated Sfrp1 gene delivery improve cardiac function and reduce apoptosis in mice with TAC-induced heart failure?
Sfrp1 gene delivery via AAV9 vector attenuates TAC-induced cardiac dysfunction in mice by inhibiting Wnt signaling-mediated apoptosis.
Pan et al. (2018) studied Hemodynamic overload-induced cardiac dysfunction. AAV9-Sfrp1 viral vector was evaluated on Cardiac systolic and diastolic functions and myocardial apoptosis. AAV9 viral vector delivery of Sfrp1 attenuated TAC-induced cardiac dysfunction and improved systolic and diastolic functions by inhibiting Wnt signaling pathway-mediated apoptosis in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: